Novo Nordisk has announced positive results from a Phase 3 study assessing the efficacy and safety of concizumab, its prophylactic treatment of hemophilia A or B with inhibitors.
Researchers in Finland and the US have identified a gene that
predisposes people to one of the most common causes of coronary
heart disease, raising the hope that it could represent a new
target for drug treatment.